ARS Pharmaceuticals, Inc Working Capital to Net Assets Ratio
ARS Pharmaceuticals, Inc working capital to net assets ratio. ARS Pharmaceuticals, Inc (SPRY) has a Working Capital to Net Assets ratio of 215.1% as of December 2025. Working capital of $245.75 Million (current assets of $284.90 Million minus current liabilities of $39.15 Million) is measured against net assets of $114.26 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check ARS Pharmaceuticals, Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of ARS Pharmaceuticals, Inc (2018–2025)
Working capital to net assets ratio of ARS Pharmaceuticals, Inc from 2018 to 2025. This chart shows how ARS Pharmaceuticals, Inc's Working Capital to Net Assets ratio has evolved across 8 annual periods from 2018 to 2025. As of December 2025, the ratio stands at 215.1%, reflecting working capital of $245.75 Million against net assets of $114.26 Million USD. See defensive interval ratio of ARS Pharmaceuticals, Inc to measure how many days the company can operate on defensive assets alone.
ARS Pharmaceuticals, Inc Working Capital to Net Assets Ratio by Year (2018–2025)
ARS Pharmaceuticals, Inc working capital to net assets ratio by year from 2018 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for ARS Pharmaceuticals, Inc from 2018 to 2025, covering 8 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see SPRY total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 215.1% | $245.75 Million | $114.26 Million | $284.90 Million | $39.15 Million | ▲ +94.0 pp |
| 2024 | 121.1% | $310.86 Million | $256.80 Million | $334.30 Million | $23.44 Million | ▲ +21.7 pp |
| 2023 | 99.3% | $229.17 Million | $230.76 Million | $231.56 Million | $2.39 Million | ▼ -0.5 pp |
| 2022 | 99.8% | $272.26 Million | $272.89 Million | $277.70 Million | $5.44 Million | ▲ +267.8 pp |
| 2021 | -168.0% | $52.54 Million | $-31.27 Million | $60.73 Million | $8.19 Million | ▼ -38.7 pp |
| 2020 | -129.3% | $18.17 Million | $-14.05 Million | $26.38 Million | $8.21 Million | ▼ -261.4 pp |
| 2019 | 132.0% | $-7.40 Million | $-5.60 Million | $10.53 Million | $17.93 Million | ▲ +46.1 pp |
| 2018 | 85.9% | $15.63 Million | $18.20 Million | $20.78 Million | $5.14 Million | — |